EcoDrugPlus

Eph Receptor A3

Ensembl ID : ENSDARG00000039373
Gene Symbol: EPHA3
5 Enzyme and pathways 5 Cross references
216 Possible Orthologues:

Eph Receptor B4b

Ensembl ID : ENSDARG00000027112
Gene Symbol: EPHB4B
5 Cross references
170 Possible Orthologues:

Epidermal Growth Factor Receptor A (Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog, Avian)

Ensembl ID : ENSDARG00000013847
Gene Symbol: EGFRA
40 Enzyme and pathways 5 Cross references
212 Possible Orthologues:

Epidermal Growth Factor Receptor-Like

Ensembl ID : ENSDARG00000056909
Gene Symbol: LOC571431
5 Cross references
213 Possible Orthologues:

Epoxide Hydrolase 2, Cytoplasmic

Ensembl ID : ENSDARG00000040255
Gene Symbol: EPHX2
10 Enzyme and pathways 5 Cross references
204 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSDARG00000026294
Gene Symbol: ERBB2
28 Enzyme and pathways 5 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3a

Ensembl ID : ENSDARG00000006202
Gene Symbol: ERBB3A
5 Cross references
211 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3b

Ensembl ID : ENSDARG00000036993
Gene Symbol: ERBB3B
23 Enzyme and pathways 5 Cross references
210 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4a

Ensembl ID : ENSDARG00000063207
Gene Symbol: ERBB4A
29 Enzyme and pathways 5 Cross references
223 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4b

Ensembl ID : ENSDARG00000089536
Gene Symbol: ERBB4B
5 Cross references
225 Possible Orthologues:

Estrogen Receptor 1

Ensembl ID : ENSDARG00000004111
Gene Symbol: ESR1
27 Enzyme and pathways 5 Cross references
215 Possible Orthologues:

Estrogen Receptor 2a

Ensembl ID : ENSDARG00000016454
Gene Symbol: ESR2A
5 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).